Linda Grais

Insider · Director · ICLR

Linda Grais files insider transactions with the SEC as a director of Icon (ICLR). We hold 1 disclosed purchase or sale filed since 3 March 2009, 1 of them in the last 90 days.

Files forICLR
Disclosed buys and sells1 in all, 1 in the last 90 days
Last disclosure12 August 2026

Positions held

6 posts we hold — a term names its own dates; a run of filings only says when they filed

Filed 10 August 2026 — 11 August 2026Director · Icon (ICLR)7 Form 4 lines · source: SEC Form 4
Filed 28 January 2019 — 11 June 2026Director · Corvus Pharmaceuticals (CRVS)14 Form 4 lines · source: SEC Form 4
Filed 27 February 2009 — 30 January 2024Director · ARCA biopharma (ABIO)17 Form 4 lines · source: SEC Form 4
Filed 12 October 2015 — 1 July 2021Director · PRA Health Sciences (PRAH)8 Form 4 lines · source: SEC Form 4
Filed 14 January 2019 — 10 June 2021Director · Zosano Pharma (ZSAN)6 Form 4 lines · source: SEC Form 4
Filed 15 July 2013 — 11 December 2017President and CEO · Ocera Therapeutics (OCRX)25 Form 4 lines · source: SEC Form 4

Everything they disclosed

77 entries, newest first — one per disclosure report, one per Form 4 line

exercised options over 1,732 shares of IconSEC Form 412 August 2026Ordinary Shares · traded 10 August 2026 · filed 12 August 2026
▼ sold on the open market 87 shares of IconSEC Form 412 August 2026Ordinary Shares · traded 11 August 2026 · filed 12 August 2026
▼ sold on the open market 97 shares of IconSEC Form 412 August 2026Ordinary Shares · traded 11 August 2026 · filed 12 August 2026
▼ sold on the open market 590 shares of IconSEC Form 412 August 2026Ordinary Shares · traded 11 August 2026 · filed 12 August 2026
▼ sold on the open market 67 shares of IconSEC Form 412 August 2026Ordinary Shares · traded 11 August 2026 · filed 12 August 2026
exercised options over 1,732 shares of Icon (a derivative holding)SEC Form 412 August 2026Restricted Share Units · traded 10 August 2026 · filed 12 August 2026
was granted 1,324 shares of Icon (a derivative holding)SEC Form 412 August 2026Restricted Share Units · traded 10 August 2026 · filed 12 August 2026
was granted 15,000 shares of Corvus Pharmaceuticals (a derivative holding)SEC Form 415 June 2026Stock Option (Right to Buy) · traded 11 June 2026 · filed 15 June 2026
was granted 15,000 shares of Corvus Pharmaceuticals (a derivative holding)SEC Form 416 June 2025Stock Option (Right to Buy) · traded 12 June 2025 · filed 16 June 2025
was granted 15,000 shares of Corvus Pharmaceuticals (a derivative holding)SEC Form 417 June 2024Stock Option (Right to Buy) · traded 13 June 2024 · filed 17 June 2024
was granted 6,000 shares of ARCA biopharma (a derivative holding)SEC Form 431 January 2024Stock Option (right to buy) · traded 30 January 2024 · filed 31 January 2024
was granted 15,000 shares of Corvus Pharmaceuticals (a derivative holding)SEC Form 48 December 2023Stock Option (Right to Buy) · traded 6 December 2023 · filed 8 December 2023
was granted 15,000 shares of Corvus Pharmaceuticals (a derivative holding)SEC Form 420 June 2023Stock Option (Right to Buy) · traded 15 June 2023 · filed 20 June 2023
▲ bought on the open market 10,000 shares of Corvus PharmaceuticalsSEC Form 416 May 2023Common Stock · traded 15 May 2023 · filed 16 May 2023
was granted 6,000 shares of ARCA biopharma (a derivative holding)SEC Form 419 December 2022Stock Option (right to buy) · traded 15 December 2022 · filed 19 December 2022
was granted 15,000 shares of Corvus Pharmaceuticals (a derivative holding)SEC Form 415 August 2022Stock Option (Right to Buy) · traded 11 August 2022 · filed 15 August 2022
was granted 15,000 shares of Corvus Pharmaceuticals (a derivative holding)SEC Form 417 June 2022Stock Option (Right to Buy) · traded 15 June 2022 · filed 17 June 2022
was granted 15,000 shares of Corvus Pharmaceuticals (a derivative holding)SEC Form 413 September 2021Stock Option (Right to Buy) · traded 9 September 2021 · filed 13 September 2021
returned to the issuer 9,683 shares of PRA Health SciencesSEC Form 41 July 2021Common Stock · traded 1 July 2021 · filed 1 July 2021
was granted 15,000 shares of Corvus Pharmaceuticals (a derivative holding)SEC Form 416 June 2021Stock Option (Right to Buy) · traded 15 June 2021 · filed 16 June 2021
was granted 15,000 shares of Zosano PharmaSEC Form 414 June 2021Common Stock · traded 10 June 2021 · filed 14 June 2021
was granted 30,000 shares of Zosano Pharma (a derivative holding)SEC Form 414 June 2021Stock Option (Right to Buy) · traded 10 June 2021 · filed 14 June 2021
was granted 250 shares of PRA Health SciencesSEC Form 43 June 2021Common Stock · traded 1 June 2021 · filed 3 June 2021
was granted 12,000 shares of ARCA biopharma (a derivative holding)SEC Form 413 January 2021Stock Option (right to buy) · traded 12 January 2021 · filed 13 January 2021
was granted 7,500 shares of Zosano PharmaSEC Form 429 June 2020Common Stock · traded 25 June 2020 · filed 29 June 2020
was granted 15,000 shares of Corvus Pharmaceuticals (a derivative holding)SEC Form 412 June 2020Stock Option (Right to Buy) · traded 9 June 2020 · filed 12 June 2020
was granted 15,000 shares of Zosano Pharma (a derivative holding)SEC Form 45 June 2020Stock Option (right to buy) · traded 3 June 2020 · filed 5 June 2020
was granted 15,000 shares of Zosano Pharma (a derivative holding)SEC Form 45 June 2020Stock Option (right to buy) · traded 3 June 2020 · filed 5 June 2020
was granted 1,324 shares of PRA Health SciencesSEC Form 420 May 2020Common Stock · traded 18 May 2020 · filed 20 May 2020
was granted 15,000 shares of Corvus Pharmaceuticals (a derivative holding)SEC Form 423 March 2020Stock Option (Right to Buy) · traded 19 March 2020 · filed 23 March 2020
was granted 15,000 shares of Corvus Pharmaceuticals (a derivative holding)SEC Form 424 June 2019Stock Option (Right to Buy) · traded 20 June 2019 · filed 24 June 2019
was granted 1,436 shares of PRA Health SciencesSEC Form 45 June 2019Common Stock · traded 3 June 2019 · filed 5 June 2019
was granted 30,000 shares of Corvus Pharmaceuticals (a derivative holding)SEC Form 430 January 2019Stock Option (Right to Buy) · traded 28 January 2019 · filed 30 January 2019
was granted 25,000 shares of Zosano Pharma (a derivative holding)SEC Form 416 January 2019Stock Option (right to buy) · traded 14 January 2019 · filed 16 January 2019
was granted 1,307 shares of PRA Health SciencesSEC Form 425 June 2018Common Stock · traded 21 June 2018 · filed 25 June 2018
was granted 8,000 shares of ARCA biopharma (a derivative holding)SEC Form 45 March 2018Stock Option (right to buy) · traded 1 March 2018 · filed 5 March 2018
returned to the issuer 230,000 shares of Ocera TherapeuticsSEC Form 411 December 2017Common Stock · traded 11 December 2017 · filed 11 December 2017
returned to the issuer 70,000 shares of Ocera TherapeuticsSEC Form 411 December 2017Common Stock · traded 11 December 2017 · filed 11 December 2017
returned to the issuer 289,200 shares of Ocera Therapeutics (a derivative holding)SEC Form 411 December 2017Stock Option (Right to Buy) · traded 11 December 2017 · filed 11 December 2017
returned to the issuer 348,600 shares of Ocera Therapeutics (a derivative holding)SEC Form 411 December 2017Stock Option (Right to Buy) · traded 11 December 2017 · filed 11 December 2017
returned to the issuer 160,000 shares of Ocera Therapeutics (a derivative holding)SEC Form 411 December 2017Stock Option (Right to Buy) · traded 11 December 2017 · filed 11 December 2017
returned to the issuer 491,550 shares of Ocera Therapeutics (a derivative holding)SEC Form 411 December 2017Stock Option (Right to Buy) · traded 11 December 2017 · filed 11 December 2017
returned to the issuer 37,500 shares of Ocera Therapeutics (a derivative holding)SEC Form 411 December 2017Stock Option (Right to Buy) · traded 11 December 2017 · filed 11 December 2017
returned to the issuer 30,826 shares of Ocera Therapeutics (a derivative holding)SEC Form 411 December 2017Stock Option (Right to Buy) · traded 11 December 2017 · filed 11 December 2017
returned to the issuer 30,827 shares of Ocera Therapeutics (a derivative holding)SEC Form 411 December 2017Stock Option (Right to Buy) · traded 11 December 2017 · filed 11 December 2017
returned to the issuer 11,969 shares of Ocera Therapeutics (a derivative holding)SEC Form 411 December 2017Stock Option (Right to Buy) · traded 11 December 2017 · filed 11 December 2017
was granted 1,318 shares of PRA Health SciencesSEC Form 414 July 2017Common Stock · traded 12 July 2017 · filed 14 July 2017
was granted 230,000 shares of Ocera TherapeuticsSEC Form 430 March 2017Common Stock · traded 29 March 2017 · filed 30 March 2017
was granted 8,000 shares of ARCA biopharma (a derivative holding)SEC Form 421 February 2017Stock Option (right to buy) · traded 16 February 2017 · filed 21 February 2017
was granted 289,200 shares of Ocera Therapeutics (a derivative holding)SEC Form 416 December 2016Stock Option (Right to Buy) · traded 15 December 2016 · filed 16 December 2016
▲ bought on the open market 7,000 shares of Ocera TherapeuticsSEC Form 48 December 2016Common Stock · traded 7 December 2016 · filed 8 December 2016
was granted 1,466 shares of PRA Health SciencesSEC Form 420 June 2016Common Stock · traded 17 June 2016 · filed 20 June 2016
▲ bought on the open market 3,000 shares of Ocera TherapeuticsSEC Form 47 March 2016Common Stock · traded 4 March 2016 · filed 7 March 2016
was granted 8,000 shares of ARCA biopharma (a derivative holding)SEC Form 416 February 2016Stock Option (right to buy) · traded 11 February 2016 · filed 16 February 2016
▲ bought on the open market 10,000 shares of Ocera TherapeuticsSEC Form 425 January 2016Common Stock · traded 22 January 2016 · filed 25 January 2016
▲ bought on the open market 10,000 shares of Ocera TherapeuticsSEC Form 419 January 2016Common Stock · traded 15 January 2016 · filed 19 January 2016
was granted 348,600 shares of Ocera Therapeutics (a derivative holding)SEC Form 47 January 2016Stock Option (Right to Buy) · traded 6 January 2016 · filed 7 January 2016
was granted 116,200 shares of Ocera Therapeutics (a derivative holding)SEC Form 47 January 2016Stock Option (Right to Buy) · traded 6 January 2016 · filed 7 January 2016
was granted 2,582 shares of PRA Health SciencesSEC Form 413 October 2015Common Stock · traded 12 October 2015 · filed 13 October 2015
was granted 160,000 shares of Ocera Therapeutics (a derivative holding)SEC Form 422 June 2015Stock Option (Right to Buy) · traded 18 June 2015 · filed 22 June 2015
▲ bought on the open market 30,000 shares of Ocera TherapeuticsSEC Form 46 May 2015Common Stock · traded 6 May 2015 · filed 6 May 2015
was granted 8,000 shares of ARCA biopharma (a derivative holding)SEC Form 417 February 2015Stock Option (right to buy) · traded 12 February 2015 · filed 17 February 2015
▲ bought on the open market 10,000 shares of Ocera TherapeuticsSEC Form 415 July 2014Common Stock · traded 11 July 2014 · filed 15 July 2014
was granted 75,000 shares of Ocera Therapeutics (a derivative holding)SEC Form 413 June 2014Stock Option (Right to Buy) · traded 11 June 2014 · filed 13 June 2014
was granted 8,000 shares of ARCA biopharma (a derivative holding)SEC Form 413 February 2014Stock Option (right to buy) · traded 11 February 2014 · filed 13 February 2014
was granted 491,550 shares of Ocera Therapeutics (a derivative holding)SEC Form 423 December 2013Stock Option (Right to Buy) · traded 13 August 2013 · filed 23 December 2013
was granted 16,000 shares of ARCA biopharma (a derivative holding)SEC Form 419 September 2013Stock Option (right to buy) · traded 17 September 2013 · filed 19 September 2013
was granted 7,417 shares of ARCA biopharma (a derivative holding)SEC Form 419 September 2013Stock Option (right to buy) · traded 17 September 2013 · filed 19 September 2013
was granted 583 shares of ARCA biopharma (a derivative holding)SEC Form 430 July 2013Option to Purchase Common Stock (right to buy) · traded 26 July 2013 · filed 30 July 2013
was granted 11,969 shares of Ocera Therapeutics (a derivative holding)SEC Form 417 July 2013Employee stock option (right to buy) · traded 15 July 2013 · filed 17 July 2013
was granted 61,653 shares of Ocera Therapeutics (a derivative holding)SEC Form 417 July 2013Employee stock option (right to buy) · traded 15 July 2013 · filed 17 July 2013
was granted 3,500 shares of ARCA biopharma (a derivative holding)SEC Form 414 February 2012Option to Purchase Common Stock · traded 10 February 2012 · filed 14 February 2012
was granted 3,500 shares of ARCA biopharma (a derivative holding)SEC Form 414 February 2012Option to Purchase Common Stock · traded 10 February 2012 · filed 14 February 2012
▼ sold on the open market 23,600 shares of ARCA biopharmaSEC Form 430 March 2010Common Stock · traded 29 March 2010 · filed 30 March 2010
▼ sold on the open market 187,209 shares of ARCA biopharmaSEC Form 430 March 2010Common Stock · traded 29 March 2010 · filed 30 March 2010
was granted 3,500 shares of ARCA biopharma (a derivative holding)SEC Form 49 February 2010Option to Purchase Common Stock · traded 5 February 2010 · filed 9 February 2010
was granted 7,500 shares of ARCA biopharma (a derivative holding)SEC Form 43 March 2009Option to Purchase Common Stock · traded 27 February 2009 · filed 3 March 2009

Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.